24 April 2025NewsAmericasDean Pelletier

Strategic IP protection for biotech-related GenAI

Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AI is transforming top 100 innovators, shows index

23 January 2026 Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.

Americas

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

22 January 2026 New rankings from LSIPR’s sister title spotlight the firms and lawyers that are most successfully navigating the volatile world of trade secrets, from ‘prompt injections’ to billion-dollar retrials.